StemCell Therapy

PTC Therapeutics (NASDAQ: PTCT) and Keryx Biopharmaceuticals (NASDAQ:KERX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.

Institutional and Insider Ownership

81.4% of PTC Therapeutics shares are held by institutional investors. Comparatively, 65.2% of Keryx Biopharmaceuticals shares are held by institutional investors. 8.1% of PTC Therapeutics shares are held by insiders. Comparatively, 3.1% of Keryx Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

PTC Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500. Comparatively, Keryx Biopharmaceuticals has a beta of 5.23, indicating that its stock price is 423% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for PTC Therapeutics and Keryx Biopharmaceuticals, as provided by MarketBeat.com.

PTC Therapeutics currently has a consensus target price of $15.44, suggesting a potential downside of 26.21%. Keryx Biopharmaceuticals has a consensus target price of $7.50, suggesting a potential downside of 1.32%. Given Keryx Biopharmaceuticals stronger consensus rating and higher probable upside, analysts clearly believe Keryx Biopharmaceuticals is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and Keryx Biopharmaceuticals net margins, return on equity and return on assets.

Earnings & Valuation

This table compares PTC Therapeutics and Keryx Biopharmaceuticals top-line revenue, earnings per share and valuation.

PTC Therapeutics has higher revenue and earnings than Keryx Biopharmaceuticals. PTC Therapeutics is trading at a lower price-to-earnings ratio than Keryx Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats Keryx Biopharmaceuticals on 7 of the 12 factors compared between the two stocks.

About PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.

About Keryx Biopharmaceuticals

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. Auryxia is marketed in Japan under the brand name Riona. It is investigating the use of ferric citrate for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent (NDD), CKD and NDD-CKD. It focuses on Keryx Patient Plus program to assist with patient accessibility to Auryxia. It has completed a Phase II clinical trial and a Phase III clinical trial of ferric citrate to gain Food and Drug Administration approval to use ferric citrate in patients with NDD-CKD.

Receive News & Ratings for PTC Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Read more here:
Critical Analysis: PTC Therapeutics (PTCT) & Keryx Biopharmaceuticals (KERX) - Dispatch Tribunal

This entry was posted on September 2, 2017 at 9:40 pm and is filed under Stem Cell kidney Failure. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |